|
|
INSR |
insulin receptor |
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- IRS activation
- Signal attenuation
- Insulin receptor signalling cascade
- Signaling by Insulin receptor
- Insulin receptor recycling
|
- Insulin human
- Insulin lispro
- Insulin glargine
- Insulin pork
- Mecasermin
- Insulin aspart
- Insulin detemir
- Insulin glulisine
- Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
- NN344
- AT1391
- Linsitinib
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- Chromic chloride
- Insulin beef
- Insulin degludec
- Insulin argine
- Insulin peglispro
- Insulin tregopil
- Fostamatinib
- Brigatinib
- Mecasermin rinfabate
- BMS-754807
- KW-2450 free base
|
- Leprechaunism ; Donohue syndrome
- Rabson-Mendenhall syndrome
|
|
|
JAK1 |
Janus kinase 1 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- ISG15 antiviral mechanism
- Interleukin-7 signaling
- Interleukin-7 signaling
- Other interleukin signaling
- RAF/MAP kinase cascade
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-35 Signalling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Interleukin-21 signaling
- Interferon alpha/beta signaling
- Interleukin receptor SHC signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- IFNG signaling activates MAPKs
- Evasion by RSV of host interferon responses
- PD-L1(CD274) glycosylation and translocation to plasma membrane
|
- Myricetin
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Fedratinib
- Filgotinib
- Abrocitinib
- Upadacitinib
- Pralsetinib
- Ivarmacitinib
|
|
|
|
JAK2 |
Janus kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Prolactin receptor signaling
- Prolactin receptor signaling
- Signaling by SCF-KIT
- Signaling by Leptin
- RMTs methylate histone arginines
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF activation
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cyclin D associated events in G1
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- IFNG signaling activates MAPKs
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Factors involved in megakaryocyte development and platelet production
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- XL019
- 5-phenyl-1H-indazol-3-amine
- 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
- 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
- Ruxolitinib
- Tofacitinib
- Pacritinib
- Baricitinib
- Entrectinib
- Fostamatinib
- Fedratinib
- Abrocitinib
- Zanubrutinib
- Pralsetinib
|
|
|
|
JAK3 |
Janus kinase 3 |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by ALK
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-21 signaling
- Interleukin receptor SHC signaling
- Potential therapeutics for SARS
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- R-348
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Zanubrutinib
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
|
MPL |
MPL proto-oncogene, thrombopoietin receptor |
- Platelet Aggregation (Plug Formation)
|
- Romiplostim
- SB-559448
- Eltrombopag
- Thrombopoietin
- Avatrombopag
- Lusutrombopag
|
- Congenital amegakaryocytic thrombocytopenia (CAMT)
|
|
|
MTDH |
metadherin |
|
|
|
|
|
NEDD4 |
NEDD4 E3 ubiquitin protein ligase |
- ISG15 antiviral mechanism
- Downregulation of ERBB4 signaling
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
NTRK1 |
neurotrophic receptor tyrosine kinase 1 |
- PLC-gamma1 signalling
- Signalling to RAS
- ARMS-mediated activation
- ARMS-mediated activation
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- NGF-independant TRKA activation
- TRKA activation by NGF
- TRKA activation by NGF
- Signalling to p38 via RIT and RIN
- PI3K/AKT activation
- PI3K/AKT activation
- Signalling to STAT3
|
- Amitriptyline
- Imatinib
- Regorafenib
- Entrectinib
- Fostamatinib
- Cenegermin
- Larotrectinib
- Pralsetinib
|
- Neuroblastoma
- Thyroid cancer
|
|
|
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- Extra-nuclear estrogen signaling
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK in cancer
- Signaling by LTK
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Co-stimulation by ICOS
|
- ATP
- Caffeine
- XL765
- Wortmannin
- Pilaralisib
- Alpelisib
- Copanlisib
|
|
|
|
PIK3CD |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
- PIP3 activates AKT signaling
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 dependent PI3K/Akt signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by CSF1 (M-CSF) in myeloid cells
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Co-stimulation by ICOS
|
- Caffeine
- XL765
- TG100-115
- 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
- Idelalisib
- Duvelisib
- Fostamatinib
- Copanlisib
- Umbralisib
|
|
|
|
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- GP1b-IX-V activation signalling
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- RHOF GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Signaling by LTK in cancer
- Signaling by LTK
- Co-stimulation by ICOS
|
- SF1126
- Enzastaurin
- Wortmannin
|
|
|
|
PIK3R2 |
phosphoinositide-3-kinase regulatory subunit 2 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- Downstream signal transduction
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK in cancer
- Signaling by LTK
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Co-stimulation by ICOS
|
|
|
|
|
PIK3R3 |
phosphoinositide-3-kinase regulatory subunit 3 |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Extra-nuclear estrogen signaling
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Co-stimulation by ICOS
|
|
|
|
|
PLCG1 |
phospholipase C gamma 1 |
- ISG15 antiviral mechanism
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PLCG1 events in ERBB2 signaling
- DAG and IP3 signaling
- PLC-gamma1 signalling
- Synthesis of IP3 and IP4 in the cytosol
- Downstream signal transduction
- Signaling by ALK
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- Role of phospholipids in phagocytosis
- PECAM1 interactions
- EGFR interacts with phospholipase C-gamma
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Role of second messengers in netrin-1 signaling
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated cell proliferation
- Constitutive Signaling by EGFRvIII
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RET signaling
- Activated NTRK2 signals through PLCG1
- Activated NTRK2 signals through PLCG1
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through PLCG1
- FCGR3A-mediated IL10 synthesis
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by ALK fusions and activated point mutants
|
|
|
|
|
PTPN11 |
protein tyrosine phosphatase non-receptor type 11 |
- Interleukin-6 signaling
- PI3K Cascade
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- GPVI-mediated activation cascade
- Prolactin receptor signaling
- PIP3 activates AKT signaling
- Spry regulation of FGF signaling
- Signaling by SCF-KIT
- GAB1 signalosome
- Downstream signal transduction
- PECAM1 interactions
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signaling by Leptin
- Co-inhibition by CTLA4
- Co-inhibition by PD-1
- Signal regulatory protein family interactions
- Netrin mediated repulsion signals
- Platelet sensitization by LDL
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- FRS-mediated FGFR2 signaling
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Regulation of IFNG signaling
- RET signaling
- Interleukin-20 family signaling
- MET activates PTPN11
- Regulation of RUNX1 Expression and Activity
- Interleukin-37 signaling
- Activated NTRK2 signals through FRS2 and FRS3
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- FLT3 Signaling
- STAT5 Activation
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Co-inhibition by BTLA
|
|
- Metachondromatosis
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
|
PTPN6 |
protein tyrosine phosphatase non-receptor type 6 |
- GPVI-mediated activation cascade
- Regulation of KIT signaling
- Signaling by ALK
- PECAM1 interactions
- Co-inhibition by PD-1
- Signal regulatory protein family interactions
- Platelet sensitization by LDL
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- CD22 mediated BCR regulation
- Neutrophil degranulation
- Interferon gamma signaling
- Regulation of IFNG signaling
- Interleukin-37 signaling
- Interferon alpha/beta signaling
- Interleukin receptor SHC signaling
- Regulation of IFNA/IFNB signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Nuclear events stimulated by ALK signaling in cancer
- Growth hormone receptor signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Co-inhibition by BTLA
|
|
|
|
|
PTPRF |
protein tyrosine phosphatase receptor type F |
- Receptor-type tyrosine-protein phosphatases
- Insulin receptor recycling
- Synaptic adhesion-like molecules
|
|
|
|
|
RPTOR |
regulatory associated protein of MTOR complex 1 |
- Macroautophagy
- MTOR signalling
- mTORC1-mediated signalling
- HSF1-dependent transactivation
- Energy dependent regulation of mTOR by LKB1-AMPK
- TP53 Regulates Metabolic Genes
- Regulation of PTEN gene transcription
- Amino acids regulate mTORC1
|
|
|
|
|
SHC1 |
SHC adaptor protein 1 |
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signalling to RAS
- SHC1 events in EGFR signaling
- Tie2 Signaling
- Integrin signaling
- XBP1(S) activates chaperone genes
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- RET signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
|
|
SOCS1 |
suppressor of cytokine signaling 1 |
- Interleukin-7 signaling
- Regulation of KIT signaling
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- Interleukin-4 and Interleukin-13 signaling
- Interferon gamma signaling
- Regulation of IFNG signaling
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- Growth hormone receptor signaling
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|